Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1991-2-7
|
| pubmed:abstractText |
We designed a protocol that included 2 months of intensive Cytoxan (cyclophosphamide; Bristol-Myers Co, Evansville, IN), high-dose methotrexate (MTX), high-dose cytarabine (ara-C), and vincristine (HiC-COM) to improve event-free survival (EFS) for patients with advanced-stage Burkitt's lymphoma and B-cell acute lymphoblastic leukemia (ALL). We also wished to test the feasibility of rapidly cycling Cytoxan and high-dose ara-C based on signs of early marrow recovery. Twenty patients including 12 with stage III Burkitt's lymphoma and eight with stage IV Burkitt's lymphoma or B-cell ALL were entered onto this pilot study. The rate of complete remission was 95%. Four patients have relapsed. The 2-year actuarial EFS was 75% (median follow-up, 37 months). Two of the initial five patients developed transverse myelitis, which we believe may have been secondary to the concomitant administration of intrathecal (IT) and high-dose systemic ara-C. We conclude that this short but intensive regimen is highly effective for patients with advanced Burkitt's lymphoma and B-cell ALL. EFS has improved over previous less intensive regimens, and is comparable to regimens of longer duration.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
133-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1985162-Adolescent,
pubmed-meshheading:1985162-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1985162-Burkitt Lymphoma,
pubmed-meshheading:1985162-Child,
pubmed-meshheading:1985162-Child, Preschool,
pubmed-meshheading:1985162-Cyclophosphamide,
pubmed-meshheading:1985162-Cytarabine,
pubmed-meshheading:1985162-Drug Administration Schedule,
pubmed-meshheading:1985162-Feasibility Studies,
pubmed-meshheading:1985162-Female,
pubmed-meshheading:1985162-Follow-Up Studies,
pubmed-meshheading:1985162-Humans,
pubmed-meshheading:1985162-Male,
pubmed-meshheading:1985162-Methotrexate,
pubmed-meshheading:1985162-Neoplasm Staging,
pubmed-meshheading:1985162-Pilot Projects,
pubmed-meshheading:1985162-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:1985162-Remission Induction,
pubmed-meshheading:1985162-Survival Rate,
pubmed-meshheading:1985162-Vincristine
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
|
| pubmed:affiliation |
Division of Pediatric Hematology/Oncology, Boston Floating Hospital, MA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|